Of these 33 diseases, 22 showed significant dose–response associations, with HRs per 280 g per week higher intake ranging from 1.16 (95% CI 1.04–1.30) for lung cancer to 1.94 (1.43–2.63) for purpura and other hemorrhagic conditions (D69) and 1.20 (1.16–1.24) for the aggregated CKB new alcohol-associated diseases. This evidence concerns the gene CKB and lung cancer.